Waterstone Pharmaceuticals, Inc., is an Indiana-based company with its main manufacturing operations in China. It aspires to be a leading developer and manufacturer of active pharmaceutical ingredients and finished pharmaceutical products. Waterstone’s business focus is to take advantage of the high-quality and lost-cost value proposition and to capture the rapidly growing China pharmaceutical market opportunity. Waterstone has developed and optimized six generic drug API processes, which are ready to scale up for U.S. FDA Drug Master File filing. The company has a strong management team with seasoned professionals in pharmaceutical manufacturing, quality control, and regulation. Meanwhile rigorous cGMP procedure and systematic training to all employees will be emphasized to ensure products’ consistent global-standard quality. Waterstone already has contracts and an ongoing relationship with Merck and Eli Lilly.